Equilibrative Nucleoside Transporter 1
"Equilibrative Nucleoside Transporter 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of equilibrative nucleoside transporter proteins that is sensitive to inhibition by 4-nitrobenzylthioinosine.
| Descriptor ID |
D033721
|
| MeSH Number(s) |
D12.776.157.530.625.750.500.500 D12.776.157.530.937.532.500 D12.776.543.585.625.750.500.500 D12.776.543.585.937.563.500
|
| Concept/Terms |
Equilibrative Nucleoside Transporter 1- Equilibrative Nucleoside Transporter 1
- Equilibrative NBMPR-Sensitive Nucleoside Transporter
- Equilibrative NBMPR Sensitive Nucleoside Transporter
- Equilibrative Nitrobenzylmercaptopurine Riboside-Sensitive Nucleoside Transporter
- Equilibrative Nitrobenzylmercaptopurine Riboside Sensitive Nucleoside Transporter
- SLC29A1 Transporter
- Solute Carrier Family 29 (Nucleoside Transporters), Member 1
|
Below are MeSH descriptors whose meaning is more general than "Equilibrative Nucleoside Transporter 1".
Below are MeSH descriptors whose meaning is more specific than "Equilibrative Nucleoside Transporter 1".
This graph shows the total number of publications written about "Equilibrative Nucleoside Transporter 1" by people in this website by year, and whether "Equilibrative Nucleoside Transporter 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Equilibrative Nucleoside Transporter 1" by people in Profiles.
-
Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744.
-
Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TR, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A. Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity. J Clin Oncol. 2013 Dec 10; 31(35):4453-61.
-
Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009 Jan; 136(1):187-95.